97 (52%) patients had advanced disease and 89 (48%) had non-advanced disease at presentation. Respectively, these groups had a similar median age at diagnosis (50 (IQR 33, 61) vs 48 (32,55)) and gender (79% female vs 73%), however they differed by race (77% Caucasian vs 90%, p=0.02). Biochemical response was more frequent in non-advanced (91%) versus advanced disease (51%, p=0.001). There was no difference among responders and non-responders PD0325901 in vivo according to gender (74% female vs 73%), race (81% Caucasian vs 74%),

or any pretreatment liver test level (ALT, AST, TB, or alkaline phosphatase), respectively. However, biochemical response was associated with older age at diagnosis (54, (45, 64)) compared to non-responders (39 (22, 54), p=0.001). 96% of patients with advanced disease and biochemical non-response had the outcome of death or liver transplant compared to 2% of responders

(p=0.001). Conclusions: Biochemical response is less frequent among AIH patients with advanced disease at presentation. Among patients with advanced disease, biochemical non-response is associated with death or transplant. Disclosures: Marwan Ghabril – Grant/Research Support: Salix Naga P. Chalasani – Consulting: Salix, Abbvie, Lilly, Boerhinger-Ingelham, Aege-rion; Grant/Research Support: Intercept, Lilly, Gilead, Cumberland, Galectin The following people have nothing to disclose: Selleck CX-4945 James R. Bailey, Gouri Sreepati, Eric S. Orman, Raj Vuppalanchi, Samer Gawrieh, Suthat Liangpunsakul, Craig

Lammert Background: Antibodies against nuclear antigens (ANA), smooth muscle (SMA) and liver kidney microssomes (LKM-1) are classically used for diagnosis and classification of autoimmune hepatitis (AIH); however, they are not good as prognostic markers during follow-up. Anti-soluble MCE公司 liver antigen (anti-SLA), anti-Ro-52, anti-liver citosol (anti-LC1), anti-Sp100 and anti-gp210 are considered non-classical antibodies (NCA) and are currently under investigation as additional markers in autoimmune liver disorders. Objectives: Our aim was to evaluate the prevalence and role of NCA in AIH and overlapping syndromes (OS) and its correlation with clinical presentation and response to treatment. Methods: One-hundred and thirty AIH and OS patients were studied, from 1989 to 2013. AIH diagnosis was based on international criteria by International Autoimmune Hepatitis Group for chronic AIH patients, and criteria described by Stravitz et al, for patients with findings compatible with acute hepatitis. Diagnosis of OS was based in EASL guidelines for cholestatic diseases. Results: Female gender was more prevalent (91%); mean age was 33±18 years. Type I AIH was diagnosed in 88% and OS in 12% of patients. ANA was the most frequent classical serological marker (73%), followed by SMA (55%). Regarding NCA, Ro52 was the most prevalent (37%), followed by SLA (19%).